Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.
Paul G
PG
Richardson
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D020869:Gene Expression Profiling; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D009367:Neoplasm Staging; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D011719:Pyrazines / Q000009:adverse effects*; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D014750:Vincristine; D000069286:Bortezomib